Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment

BACKGROUND: PARP inhibitors, such as Olaparib, have advanced the treatment of ovarian cancer by providing patients with an effective and molecularly-targeted maintenance therapy. However, all orally-administered drugs, including Olaparib, must undergo first-pass metabolism. In contrast, a nanopartic...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldwin, Paige, Ohman, Anders W, Tangutoori, Shifalika, Dinulescu, Daniela M, Sridhar, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278886/
https://www.ncbi.nlm.nih.gov/pubmed/30555227
http://dx.doi.org/10.2147/IJN.S186881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278886/
https://www.ncbi.nlm.nih.gov/pubmed/30555227
http://dx.doi.org/10.2147/IJN.S186881

Ejemplares similares